ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Sulconazole Suppresses Colorectal Cancer Immune Evasion by Inhibiting Glycolysis to Upregulate OVOL2 PARylation and Induce PANoptosis.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of PANoptosis in cancer: molecular mechanisms and therapeutic insights.Archives of toxicology · 2026Review
- Lactate as a Master Regulator of Immune Suppression: From Metabolic Waste to Epigenetic Checkpoint in Colorectal Cancer.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Colorectal cancer (CRC) progression involves metabolic reprogramming and immune evasion, but the link between glycolysis-driven epigenetics and immune checkpoints is unclear. OVOL2 is a tumor suppressor, yet its role in metabolic-immune crosstalk is unknown. In CRC cells and mouse models, we studied how OVOL2 loss enhances glycolysis and immune evasion. Multi-omics, CRISPR-Cas9, and pharmacological inhibition dissected the OVOL2-glycolysis-PD-L1 axis. Histone lactylation was assessed via immunoblotting and mutagenesis; OVOL2 PARylation by co-IP and PARP assays. Sulconazole's effects were tested in vitro/in vivo, with immune profiling by flow cytometry and multiplex IHC. OVOL2 deficiency increased glycolysis, lactate, and histone lactylation at the CD274 promoter, upregulating PD-L1 and promoting CD8+ T-cell exhaustion. Sulconazole inhibited glycolysis, reduced lactylation and PD-L1, and restored PARP1-mediated OVOL2 PARylation, inducing ASC-dependent PANoptosis. In mice, sulconazole suppressed tumor growth and metastasis. OVOL2 regulates metabolic-immune crosstalk in CRC. Sulconazole blocks glycolysis-driven PD-L1 expression and restores OVOL2 function, inducing PANoptosis and reversing immune evasion. Repurposing sulconazole offers a promising strategy for glycolytic, immunosuppressive CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.